{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:23:19Z","timestamp":1765232599491,"version":"3.37.3"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Following safety concerns regarding trimetazidine, the European Medicines Agency (EMA) recommended restrictions on its use. Our objective was to determine the impact of regulatory actions on trimetazidine utilization in Portugal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective interrupted time\u2010series analysis of monthly ambulatory pharmacy reimbursement records for the Portuguese National Health Service between January 2006 and December 2015. Regulatory actions were identified by searching the EMA, Portuguese Medicines Authority, and European Commission's websites. Concurrent factors in the same period were also identified. The main outcome was the dispensing of trimetazidine\u2010containing products per month in Portugal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two interruption periods were defined in the series: May 2011, when EMA announced it would review trimetazidine safety, and June 2012 to January 2013, when EMA announced it had reached a final opinion recommending restrictions; the European Commission approved EMA's recommendation; the Portuguese Medicines Authority issued safety alerts, changed the summary of product characteristics, and approved a direct health\u2010care professional letter; and a regional bulletin was issued.<\/jats:p><jats:p>Interruption 1 had no effect on trimetazidine use, but interruption 2 resulted in decreases in level and trend\u2014from 8.3\u00a0million defined daily doses in 2010 to 2.8\u00a0million in 2015. After interruption 2, trimetazidine use tended towards a lower steady state.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was a significant decrease in trimetazidine use in Portugal following a complex intervention that included safety alerts, changes to the summary of product characteristics, a direct health\u2010care professional letter, and a regional drug bulletin. No effect was seen when EMA announced its review of trimetazidine safety.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4585","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T06:41:58Z","timestamp":1531291318000},"page":"962-968","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of <scp>E<\/scp>uropean <scp>M<\/scp>edicines <scp>A<\/scp>gency's restrictions on trimetazidine utilization in <scp>P<\/scp>ortugal"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-6824","authenticated-orcid":false,"given":"Daniel","family":"Pinto","sequence":"first","affiliation":[{"name":"Group for Independent Academic Information, Chronic Diseases Research Center NOVA Medical School  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Silva","sequence":"additional","affiliation":[{"name":"Regulatory Affairs Specialist Fellow  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3943-1858","authenticated-orcid":false,"given":"Bruno","family":"Heleno","sequence":"additional","affiliation":[{"name":"Group for Independent Academic Information, Chronic Diseases Research Center NOVA Medical School  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-1510","authenticated-orcid":false,"given":"David Silv\u00e9rio","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Group for Independent Academic Information, Chronic Diseases Research Center NOVA Medical School  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9320-6451","authenticated-orcid":false,"given":"Isabel","family":"Santos","sequence":"additional","affiliation":[{"name":"Group for Independent Academic Information, Chronic Diseases Research Center NOVA Medical School  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-4190","authenticated-orcid":false,"given":"Pedro A.","family":"Caetano","sequence":"additional","affiliation":[{"name":"Group for Independent Academic Information, Chronic Diseases Research Center NOVA Medical School  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"WHO Collaborating Centre for International Drug Monitoring.The importance of pharmacovigilance[Internet].World Health Organization;2002[cited 2017 Jul 15]. Chapter 4 Pharmacovigilance in Drug Regulation. Available from:http:\/\/apps.who.int\/iris\/bitstream\/10665\/42493\/1\/a75646.pdf"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599100-000000000-00000"},{"key":"e_1_2_9_4_1","unstructured":"European Medicines Agency.Trimetazidine\u2014Article 31\u2014Annex II: scientific conclusions and grounds for variation to the terms of the Marketing Authorisations [Internet]. 17 Oct 2012 [cited 06\/06\/2016]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Trimetazidine_31\/WC500133921.pdf"},{"key":"e_1_2_9_5_1","unstructured":"Reversible Parkinsonism linked to trimetazidine (continued). Prescrire Int.2006Aug;15 (84):136."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2011.01008.x"},{"key":"e_1_2_9_7_1","unstructured":"Commission of the European CommunitiesCommission decision of 3.9.2012 concerning in the framework of Article 31 of Directive 2001\/83\/EC of the European Parliament and of the Council the marketing authorisations of medicinal products for human use which contain the active substance \u201ctrimetazidine\u201d\u2014annexes [Internet]. Brussels 3 September 2012 [cited 06\/06\/2016]. Available from: http:\/\/ec. europa.eu\/health\/Documents\/community\u2010register\/2012\/20120903123837\/dec_123837_en.pdf"},{"key":"e_1_2_9_8_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology ATC classification index with DDDs 2015 [Internet]. Oslo 2014 [cited 06\/06\/2016]. Available from:http:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"e_1_2_9_9_1","unstructured":"Google Trends Help.How trends data is adjusted [Internet]. Google 2017[cited 21\/01\/2017]. Available from:https:\/\/support.google.com\/trends\/answer\/4365533"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_9_11_1","unstructured":"European Medicines Agency.Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16\u201319 May 2011 [Internet]. London 20 May 2011 [cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2011\/05\/WC500106539.pdf"},{"key":"e_1_2_9_12_1","unstructured":"European Medicines Agency.Committee for Medicinal Products for Human Use (CHMP)\u2014May 2011 plenary meeting monthly report [Internet]. London 27 May 2011 [cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Committee_meeting_report\/2011\/05\/WC500106874.pdf"},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency.European Medicines Agency recommends restricting use of trimetazidine\u2010containing medicines [Internet]. London 22 June 2012 [cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2012\/06\/WC500129070.pdf"},{"key":"e_1_2_9_14_1","unstructured":"European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18\u201321 June 2012 [Internet]. Londo 22 June 2012 [cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2012\/06\/news_detail_001533.jsp&mid=WC0b01ac058004d5c1"},{"key":"e_1_2_9_15_1","unstructured":"European Medicines Agency.Trimetazidine Product Information as approved by the CHMP on 21 June 2012 pending endorsement by the European Commission [Internet]. London 22 June2012[cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2012\/06\/WC500129086.pdf"},{"key":"e_1_2_9_16_1","unstructured":"Infarmed \u2010 Autoridade Nacional do Medicamento e Produtos de Sa\u00fade I.P. Circular Informativa N.\u00b0 140\/CD\/8.1.7.Trimetazidina \u2010 recomenda\u00e7\u00e3o de restri\u00e7\u00e3o das indica\u00e7\u00f5es terap\u00eauticas [Internet]. Lisbon 22 June2012[cited 2017 Jan 22]. Available from:http:\/\/www.infarmed.pt\/documents\/15786\/1094937\/8666682.PDF\/b9e5e9d1\u2010b755\u2010413c\u2010a4aa\u2010f38702873f51?version=1.0"},{"key":"e_1_2_9_17_1","unstructured":"European Medicines Agency.Human medicines highlights newsletter Issue 41 June 2012 [Internet]. London 3 July 2012 [cited2017Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Newsletter\/2012\/07\/WC500129432.pdf"},{"key":"e_1_2_9_18_1","unstructured":"European Comission.European Commission procedures \u2010 trimetazidine: decision(2012)6196 of 03\/09\/2012 [Internet]. 3 September 2012 [cited 2017 Jan 22]. Available from:http:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/html\/ho24241.htm"},{"key":"e_1_2_9_19_1","unstructured":"European Medicines Agency.Assessment Report for trimetazidine containing medicinal products \u2010 Referral under Article 31 of Directive 2001\/83\/EC [Internet]. London 3 September 2012 [cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Trimetazidine_31\/WC500133925.pdf"},{"key":"e_1_2_9_20_1","unstructured":"European Medicines Agency.Questions and answers on the review of medicines containing trimetazidine [Internet]. Londo 3 September 2012 [cited 2017 Jan 22]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Trimetazidine_31\/WC500129195.pdf"},{"key":"e_1_2_9_21_1","unstructured":"Servier Portugal.Comunica\u00e7\u00e3o dirigida aos Profissionais de Sa\u00fade \u2010 Restri\u00e7\u00e3o das Indica\u00e7\u00f5es Terap\u00eauticas para os medicamentos que cont\u00eam trimetazidina [Internet]. 28 September 2012 [cited 2017 Jan 22]. Available from:http:\/\/www.infarmed.pt\/documents\/15786\/1411093\/DHPC_Trimetazidina.pdf"},{"key":"e_1_2_9_22_1","unstructured":"Comiss\u00e3o de Farm\u00e1cia e Terap\u00eautica da Administra\u00e7\u00e3o Regional de Sa\u00fade de Lisboa e Vale do Tejo. Boletim Terap\u00eautico n.\u00b0 1\/2013: Trimetazidina [Internet].2013[cited2017Feb 19]. Available from:http:\/\/www.arslvt.min\u2010saude.pt\/uploads\/document\/file\/449\/1_Boletim_Trimetazidina.pdf"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0291-y"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw098"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd12.150187"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2750"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.10.003"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0126-7"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T15:57:28Z","timestamp":1694275048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/pds.4585"],"URL":"https:\/\/doi.org\/10.1002\/pds.4585","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"2017-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}